{"id":"https://genegraph.clinicalgenome.org/r/23b6bb53-7aa8-437c-a38e-66e6bae7b1f7v1.0","type":"EvidenceStrengthAssertion","dc:description":"GPT2 was first reported in relation to autosomal recessive glutamate pyruvate transaminase 2 deficiency in 2014 (Iglesias et al., PMID: 24901346). This neurologic syndrome is characterized by delayed psychomotor development, moderately to severely impaired intellectual development, and poor or absent speech. More severely affected individuals show poor overall growth with progressive microcephaly, axial hypotonia, oromotor dysfunction with drooling, joint contractures, and spastic paraplegia resulting in walking difficulties. Eight variants (missense, frameshift, nonsense, and splice variants) that have been reported in 7 probands (and 22 family members) in 4 publications (PMIDs: 31471722, 29882329, 25758935, and 27601654) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence has been reached. The mechanism of pathogenicity is reported to be loss of function. This gene-disease association is also supported by its biochemical function catalyzing a reversible transamination reaction between L-alanine and 2-oxoglutarate to produce glutamate and pyruvate (PMID: 11863375), required for amino acid metabolism and neurotransmitter production. As well as its expression at increasing levels in brain during early postnatal development (PMID: 27601654) and a mouse model with decreases in postnatal brain growth and reduced alanine levels, akin to the human phenotype (PMID: 27601654). In summary, GPT2 is definitively associated with autosomal recessive glutamate pyruvate transaminase 2 deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/23b6bb53-7aa8-437c-a38e-66e6bae7b1f7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2021-10-05T11:54:27.845Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2021-10-05T11:54:44.770Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4721f1c1-d092-4358-84eb-6e0759fffc11","type":"EvidenceLine","dc:description":"Mice had  decreases in postnatal brain growth and reduced alanine levels, akin to the human phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d8d79e0-63c7-4aa9-ab6f-26dc6e71fcff","type":"Finding","dc:description":"Gpt2-null brains showed a small but consistent and significant reduction in cortical area relative to control (P < 0.03). At approximately P18, homozygous mutant mice began to demonstrate reduced motor activity. Also investigated Gpt2-null mouse brains for derangements in metabolite levels and alanine showed a strong decrease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","rdfs:label":"Gpt2-null mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e8161d15-102e-42e7-8b5b-ff3efe576001","type":"EvidenceLine","dc:description":"Expression of ALT2 protein in E. coli produced a functional a recombinant enzyme that catalyzes alanine transamination.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15d4f290-c67e-44c5-a9fb-52dba1738096","type":"Finding","dc:description":"Catalyzes a reversible transamination reaction between L-alanine and 2-oxoglutarate to produce glutamate and pyruvate, required for amino acid metabolism and neurotransmitter production. The glutamate-glutamine/lactate-alanine shuttle pathway is important in glutamatergic neurons and astrocytes, to produce glutamate, an excitatory neurotransmitter. Disruption of the production of this major neurotransmitter would be predicted to have catastrophic and generalized effects on brain function but would not be predicted to significantly affect other parts of the body since the expression of the ALT1 isoform should compensate in tissues other than the brain which expresses only ALT2. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11863375","rdfs:label":"Alanine aminotransferase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3a93f4d9-0f7e-49fa-a2f7-3928206b92e2","type":"EvidenceLine","dc:description":"In humans, through analyses of the Allen Instituteâ€™s Developmental Transcriptome Dataset, the authors observed that GPT2 mRNA is broadly expressed across all parts of the human brain throughout development and into adulthood, with highest levels in the early postnatal years as seen in mice.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/55db88b1-5ae3-42b6-bc64-b4a23ad9485c","type":"Finding","dc:description":"In mice, GPT2 was localized to mitochondria and is expressed at increasing levels in brain during early postnatal development corresponding to periods of circuit development. Gpt enzyme activity was detectable at postnatal day 1 (P1), yet enzyme activity was found to increase nearly 10-fold by P18, correlating with increases in Gpt2 protein levels. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","rdfs:label":"Brain Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0be37656-ee74-4607-afad-4e8bdfe32d19_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dccf1757-be52-4e8d-b350-fb03c93ba8f8","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dccf1757-be52-4e8d-b350-fb03c93ba8f8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expressed the recombinant wild type and mutant S153R in bacteria and measured ALT activity. Overexpression of the S153R mutant ALT2 did not change the activity, but that of wild type ALT significantly increased the activity by fivefold. Additionally, in PMID: 27601654 the authors expressed this variant in HeLa cells, finding only 37% of WT protein levels and enzymatic activity at background levels.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/dccf1757-be52-4e8d-b350-fb03c93ba8f8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25758935","allele":{"id":"https://genegraph.clinicalgenome.org/r/0096bee0-ad7e-4b26-b466-ece59b9928a1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.459C>G (p.Ser153Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA198546"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/0be37656-ee74-4607-afad-4e8bdfe32d19","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25758935","rdfs:label":"14yo","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0096bee0-ad7e-4b26-b466-ece59b9928a1"},"detectionMethod":"WES identified sequence changes of interest were confirmed in all members of the trio by conventional di-deoxy DNA sequence analysis.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"plasma alanine 143 Umol/L (normal range 240-600)","phenotypes":["obo:HP_0000369","obo:HP_0011448","obo:HP_0025190","obo:HP_0001344","obo:HP_0000252","obo:HP_0500154","obo:HP_0000341","obo:HP_0002066","obo:HP_0003487","obo:HP_0001348","obo:HP_0001252","obo:HP_0000601","obo:HP_0002307","obo:HP_0001263","obo:HP_0002353","obo:HP_0010864"],"previousTesting":true,"previousTestingDescription":"A series of genetic and metabolic tests were performed, all of which were normal including karyotype, subtelomeric FISH, FISH for Angelman syndrome/Prader-Willi, fragile X, quantitative plasma amino acids (except low alanine), urine organic acids, urine purines and pyrimidines, urine oligosaccharides, carbohydrate deficient transferrin, quantitative cerebrospinal fluid (CSF) amino acids, CSF neurotransmitter metabolites (3-O-methyldopa, 5-Hydroxyindolacetic acid, and homovanillic acid, neopterin and tetrahydrobiopterin). ","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dccf1757-be52-4e8d-b350-fb03c93ba8f8_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/1aace702-2eac-453b-9e70-0b6a4b427f6b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4dfc9af4-47d9-4a91-bc3c-e149e6f20099","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4dfc9af4-47d9-4a91-bc3c-e149e6f20099_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expressed mutated transcripts in HeLa cells. Western blot detected a scant quantity of the predicted truncated protein, consistent with the NMD expected for this nonsense variant in exon 9/12. Additionally, enzyme activity was substantially diminished to background levels.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4dfc9af4-47d9-4a91-bc3c-e149e6f20099_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","allele":{"id":"https://genegraph.clinicalgenome.org/r/0a8f01fc-003c-4743-a79e-c8da9bc9d6d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.1210C>T (p.Arg404Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8038814"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/1aace702-2eac-453b-9e70-0b6a4b427f6b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","rdfs:label":"MI1001","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0a8f01fc-003c-4743-a79e-c8da9bc9d6d6"},"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001260","obo:HP_0000750","obo:HP_0011999","obo:HP_0001249","obo:HP_0002355","obo:HP_0008947","obo:HP_0000252","obo:HP_0002028"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4dfc9af4-47d9-4a91-bc3c-e149e6f20099_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/a22045e1-f7e3-424b-a44e-45cfa07073c8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dea45d6a-634b-47f4-9c47-a4d50c5681a3","type":"EvidenceLine","dc:description":"MAF of 0.0001202 (3/24962 alleles) in the gnomAD African/African-American  population.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dea45d6a-634b-47f4-9c47-a4d50c5681a3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression in HeLa cells found reduced expression levels and substantially diminished enzymatic activity comparable to empty vector.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/dea45d6a-634b-47f4-9c47-a4d50c5681a3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","allele":{"id":"https://genegraph.clinicalgenome.org/r/5b34fbc3-ece4-4d15-8216-6f15595376af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.775T>C (p.Cys259Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/983542"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a22045e1-f7e3-424b-a44e-45cfa07073c8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","rdfs:label":"2.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5b34fbc3-ece4-4d15-8216-6f15595376af"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000750","obo:HP_0001249","obo:HP_0000252","obo:HP_0001288"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dea45d6a-634b-47f4-9c47-a4d50c5681a3_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/42a70a83-40da-4acc-b6a3-9ef3942abd14_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c3bb096-720a-44af-aaea-1c86f8611c0d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","rdfs:label":"MI1000","family":{"id":"https://genegraph.clinicalgenome.org/r/1c3bb096-720a-44af-aaea-1c86f8611c0d","type":"Family","rdfs:label":"MI1000","member":{"id":"https://genegraph.clinicalgenome.org/r/1aace702-2eac-453b-9e70-0b6a4b427f6b"}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0001249","obo:HP_0000252","obo:HP_0000750"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/1aace702-2eac-453b-9e70-0b6a4b427f6b"},"publishedLodScore":3.13,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/9161cadc-a134-4bca-a9bf-55908bf79e7b_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","rdfs:label":"Pedigree 4","estimatedLodScore":1.93,"family":{"id":"https://genegraph.clinicalgenome.org/r/9161cadc-a134-4bca-a9bf-55908bf79e7b","type":"Family","rdfs:label":"Pedigree 4","member":{"id":"https://genegraph.clinicalgenome.org/r/0170be5e-21eb-455b-b2ee-80e7374e2961","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","rdfs:label":"4.2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":36,"allele":{"id":"https://genegraph.clinicalgenome.org/r/edd67628-46c0-4af2-8933-507c6cbd70c0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.1035C>T (p.Gly345=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8038768"}},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001288","obo:HP_0001249"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6b7ec420-b337-430d-a997-b9effb97c057_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","allele":{"id":"https://genegraph.clinicalgenome.org/r/edd67628-46c0-4af2-8933-507c6cbd70c0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0001249","proband":{"id":"https://genegraph.clinicalgenome.org/r/0170be5e-21eb-455b-b2ee-80e7374e2961"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/d93d5f2f-98e3-4e64-8a32-a680b9422c7c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25758935","rdfs:label":"Mizrahi Jewish Family","estimatedLodScore":1.83,"family":{"id":"https://genegraph.clinicalgenome.org/r/d93d5f2f-98e3-4e64-8a32-a680b9422c7c","type":"Family","rdfs:label":"Mizrahi Jewish Family","member":{"id":"https://genegraph.clinicalgenome.org/r/0be37656-ee74-4607-afad-4e8bdfe32d19"}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001263","obo:HP_0001252","obo:HP_0010864","obo:HP_0001344","obo:HP_0500154"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0be37656-ee74-4607-afad-4e8bdfe32d19"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/2c6e0830-bfec-4eaf-bd3d-ffbfa5c86779_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","rdfs:label":"Pedigree 1","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/2c6e0830-bfec-4eaf-bd3d-ffbfa5c86779","type":"Family","rdfs:label":"Pedigree 1","member":{"id":"https://genegraph.clinicalgenome.org/r/aa609b26-3b86-4574-9753-05f533d68079","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","rdfs:label":"1.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/608a3acd-1742-44ef-9079-4ed0fb73590f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.812A>C (p.Asn271Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/983541"}},{"id":"https://genegraph.clinicalgenome.org/r/23a50ede-bc61-4947-b59c-9acb049cd393","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.1432_1433del (p.Val478ArgfsTer73)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2220117893"}}],"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002370","obo:HP_0001270","obo:HP_0002307","obo:HP_0000252","obo:HP_0002186","obo:HP_0001260","obo:HP_0006895","obo:HP_0002020","obo:HP_0001249","obo:HP_0002013","obo:HP_0002136","obo:HP_0001347","obo:HP_0000750","obo:HP_0012407","obo:HP_0001257","obo:HP_0001250"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/7abc6643-0632-43e0-914e-2ee3c8be8ea6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","allele":{"id":"https://genegraph.clinicalgenome.org/r/608a3acd-1742-44ef-9079-4ed0fb73590f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/9c58578e-f5e4-467d-8042-af78950598b4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31471722","allele":{"id":"https://genegraph.clinicalgenome.org/r/23a50ede-bc61-4947-b59c-9acb049cd393"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001260","obo:HP_0001249","obo:HP_0006895","obo:HP_0002013","obo:HP_0001270","obo:HP_0000750","obo:HP_0001257","obo:HP_0001250","obo:HP_0002307"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/aa609b26-3b86-4574-9753-05f533d68079"}},{"id":"https://genegraph.clinicalgenome.org/r/a6cc6811-fb78-479f-be15-aaa7024a1ec1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","rdfs:label":"MC9400","family":{"id":"https://genegraph.clinicalgenome.org/r/a6cc6811-fb78-479f-be15-aaa7024a1ec1","type":"Family","rdfs:label":"MC9400","member":{"id":"https://genegraph.clinicalgenome.org/r/7045f0b8-7da6-411b-b220-b0e9cd12d756","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","rdfs:label":"MC9401","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/165e2915-e28b-40a9-8ffe-f0c9eea0274d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.815C>T (p.Pro272Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10586688"}},"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001264","obo:HP_0000252","obo:HP_0002307","obo:HP_0001260","obo:HP_0001347","obo:HP_0008947","obo:HP_0001249","obo:HP_0000750","obo:HP_0001276"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1bfae128-a9b6-4964-942d-1bae0fc5d6b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27601654","allele":{"id":"https://genegraph.clinicalgenome.org/r/165e2915-e28b-40a9-8ffe-f0c9eea0274d"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":9,"phenotypes":["obo:HP_0001249","obo:HP_0000252"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/7045f0b8-7da6-411b-b220-b0e9cd12d756"},"publishedLodScore":3.38,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/5a50f7ed-fa0a-4a76-8957-cd6c247f819f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29882329","rdfs:label":"F1","estimatedLodScore":1.45,"family":{"id":"https://genegraph.clinicalgenome.org/r/5a50f7ed-fa0a-4a76-8957-cd6c247f819f","type":"Family","rdfs:label":"F1","member":{"id":"https://genegraph.clinicalgenome.org/r/1ff0f2b1-e966-4aac-9133-2bc136296ee7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29882329","rdfs:label":"F1-11.5","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a3ae66f6-68c7-4ecb-892b-a31d580235f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_133443.4(GPT2):c.70C>T (p.Gln24Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA396091257"}},"detectionMethod":"WES in patient F1-II.5 with Sanger confirmation in proband and family members.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002066","obo:HP_0006466","obo:HP_0001344","obo:HP_0003487","obo:HP_0002313","obo:HP_0008947","obo:HP_0000194","obo:HP_0010864","obo:HP_0002307","obo:HP_0000718","obo:HP_0007256","obo:HP_0001258","obo:HP_0001347","obo:HP_0002197","obo:HP_0000599","obo:HP_0000252","obo:HP_0009899","obo:HP_0000322"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/20e6d446-0498-4c7d-a855-da8a3d182d9a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29882329","allele":{"id":"https://genegraph.clinicalgenome.org/r/a3ae66f6-68c7-4ecb-892b-a31d580235f0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001344","obo:HP_0002307","obo:HP_0000252","obo:HP_0001347","obo:HP_0000322","obo:HP_0000194","obo:HP_0000599","obo:HP_0000718","obo:HP_0003487","obo:HP_0007256","obo:HP_0010864","obo:HP_0009899"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/1ff0f2b1-e966-4aac-9133-2bc136296ee7"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/1ff0f2b1-e966-4aac-9133-2bc136296ee7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20e6d446-0498-4c7d-a855-da8a3d182d9a","type":"EvidenceLine","dc:description":"The nonsense variant in exon 2 of 12 is predicted to result in NMD. It was found homozygous due to consanguinity. The variant has a MAF of 0.00005090 (1/19646 alleles) in the gnomAD Latino population.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20e6d446-0498-4c7d-a855-da8a3d182d9a_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1ff0f2b1-e966-4aac-9133-2bc136296ee7"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/0170be5e-21eb-455b-b2ee-80e7374e2961_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b7ec420-b337-430d-a997-b9effb97c057","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b7ec420-b337-430d-a997-b9effb97c057_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The C-to-T change would introduce a strong splice donor site 4 bp upstream of the reference splice donor at the end of exon 8. If this mutant splice donor were to engage the splice acceptor on exon 9, then it would predict a 4-bp deletion and subsequent frameshift, resulting in a nonsense mutation. The splice site was evaluated by exon trapping and as predicted, the C-to-T change in exon 8 led to a 4-bp deletion in comparing the wild-type vs. mutant splicing reaction.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6b7ec420-b337-430d-a997-b9effb97c057_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/0170be5e-21eb-455b-b2ee-80e7374e2961"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/aa609b26-3b86-4574-9753-05f533d68079_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7abc6643-0632-43e0-914e-2ee3c8be8ea6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7abc6643-0632-43e0-914e-2ee3c8be8ea6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression in HeLa cells found reduced expression levels and substantially diminished enzymatic activity comparable to empty vector.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/7abc6643-0632-43e0-914e-2ee3c8be8ea6_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9c58578e-f5e4-467d-8042-af78950598b4","type":"EvidenceLine","dc:description":"This 2-bp deletion causes a frameshift, which leads to read through of the original stop codon and extension of the C-terminus of GPT2 by 26 amino acids. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c58578e-f5e4-467d-8042-af78950598b4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression in HeLa cells found reduced expression levels and substantially diminished enzymatic activity comparable to empty vector.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9c58578e-f5e4-467d-8042-af78950598b4_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/aa609b26-3b86-4574-9753-05f533d68079"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/7045f0b8-7da6-411b-b220-b0e9cd12d756_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bfae128-a9b6-4964-942d-1bae0fc5d6b6","type":"EvidenceLine","dc:description":"MAF 0.0002979 (9/30214 alleles) in the  South Asian population.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bfae128-a9b6-4964-942d-1bae0fc5d6b6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expressed mutated transcripts in HeLa cells and enzyme activity was substantially diminished to background levels.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1bfae128-a9b6-4964-942d-1bae0fc5d6b6_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7045f0b8-7da6-411b-b220-b0e9cd12d756"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":3473,"specifiedBy":"GeneValidityCriteria8","strengthScore":15,"subject":{"id":"https://genegraph.clinicalgenome.org/r/rC6sYfrVpXM","type":"GeneValidityProposition","disease":"obo:MONDO_0014567","gene":"hgnc:18062","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_42a70a83-40da-4acc-b6a3-9ef3942abd14-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}